Prof Dr Srikumar and his research team have published an illuminating case report and literature review on Gorlin‑Goltz Syndrome in the Journal of Pharmaceutical Research, in collaboration with SRM University (India) and Universitas Negeri Surabaya (Indonesia). Their work brings much‑needed clarity to this rare hereditary cancer syndrome, spotlighting methods that could advance early detection and patient care—a powerful demonstration of SEGi’s research leadership in global health.
Gorlin‑Goltz Syndrome (also known as Gorlin syndrome or basal cell naevus syndrome) is estimated to affect approximately one in 40,000 to 60,000 people globally. Presentation often begins in childhood or adolescence, with lifelong implications: up to 90 % of patients develop recurrent jaw keratocysts, nearly all manifest multiple basal‑cell carcinomas, and serious conditions such as medulloblastoma may arise in around 5–10 % of cases.
By investigating diagnostic markers—from craniofacial anomalies to intracranial calcifications and skeletal irregularities—this report contributes practical insights for clinicians and genetic counsellors. This is why we pursue such research: to improve early recognition, tailor interventions and ultimately enhance outcomes for individuals with rare genetic conditions.
SEGi’s role in driving this interdisciplinary, international study underscores our commitment to inclusive, impactful biomedical innovation. Through meaningful collaboration and meticulous scholarship, SEGi is helping to close diagnostic gaps and inform evidence-based healthcare across borders. The full report is available at the Cross Reference DOI: https://doi.org/10.64063/3049-1681.vol.2.issue6.1
Aligning with broader global health imperatives, this research advances the United Nations Sustainable Development Goals by strengthening SDG 3: Good Health and Well-being, enhancing SDG 9: Industry, Innovation and Infrastructure, and supporting SDG 17: Partnerships for the Goals.
This event is organised in support of the following United Nations Sustainable Development Goals (SDG):
SDG 3: Good Health and Well-being
SDG 9: Industry, Innovation and Infrastructure
SDG 17: Partnerships for the Goals
